Fidelis Animal Health Announces Major Label Expansion for Ethiqa XR
Ethiqa XR, an extended-release buprenorphine, adds captive rodents and laboratory rabbits to the label for 72-hour control of post-procedural pain.
Enhancing Veterinary Practice with Ethiqa XR
Fidelis Animal Health, Inc. is excited to announce that the Food and Drug Administration (FDA) has expanded the indication of Ethiqa XR (buprenorphine extended-release injectable suspension) 1.3 mg/mL. This innovative medication is now approved for controlling post-procedural pain in a variety of laboratory and captive animals, including mice, rats, gerbils, and laboratory rabbits.
Meeting Veterinarians' Expectations
“We are thrilled to offer these new indications, which are designed to meet the high expectations of veterinarians in both general and specialty practices, as well as those in the research community,” said Michael Wells, Board Chair and CEO. “Ethiqa XR meets rigorous safety and efficacy standards and simplifies the compliance process with FDA GFI #256, emphasizing the importance of authorized medications over compounded drugs for animal healthcare.”
Innovative Technology Behind Ethiqa XR
Ethiqa XR harnesses the unique Fidelipid LAI™ technology developed by Fidelis Animal Health, allowing for impactful clinical analgesia for up to 72 hours with a single subcutaneous injection. This method prioritizes safety, avoiding harmful excipients, and adhering to cGMP standards to ensure consistent quality.
Widespread Usage in Veterinary Medicine
Since its introduction to laboratory veterinarians, Ethiqa XR has quickly gained traction, being utilized in over five hundred institutions nationwide, including top pharmaceutical companies and elite academic institutions. The use of this medication is on the rise among veterinarians who care for small mammal patients, streamlining pain management in these sensitive procedures.
Availability of Ethiqa XR
Veterinarians can easily access Ethiqa XR through major veterinary distributors such as Covetrus, Patterson, MWI Animal Health, and Midwest Veterinary Supply. This accessibility ensures that practitioners have the tools necessary to provide effective pain management for their animal patients.
Important Safety Information for Ethiqa XR
For administration, it is critical that Ethiqa XR is given only by subcutaneous injection, avoiding any other forms such as intravenous or intramuscular methods. It is essential not to use this product in animals exhibiting any respiratory issues, as it can cause sedation and decreased gastrointestinal motility. Moreover, concurrent use with NSAIDs can pose serious risks in certain animals.
About Fidelis Animal Health
Fidelis Animal Health is committed to advancing veterinary medicine through innovative pharmaceutical solutions. The company prides itself on its commitment to quality and safety, setting a standard in the industry with its proprietary formulations designed to enhance animal health.
Frequently Asked Questions
What is Ethiqa XR?
Ethiqa XR is an extended-release buprenorphine injection used for effective pain control in various laboratory and captive animals.
What animals can be treated with Ethiqa XR?
Ethiqa XR is approved for use in mice, naked mole rats, gerbils, hamsters, rats, chinchillas, guinea pigs, prairie dogs, ferrets, laboratory rabbits, and non-human primates.
How does Ethiqa XR work?
It uses Fidelis Animal Health's proprietary technology to provide 72-hour analgesia with a single administration, enhancing the comfort of animals post-procedure.
Where can veterinarians obtain Ethiqa XR?
Ethiqa XR is readily available through major veterinary distributors like Covetrus and Patterson, making it accessible for veterinary practices.
What safety precautions should be followed with Ethiqa XR?
It is crucial to administer Ethiqa XR only via subcutaneous injection and to monitor animals closely for any adverse reactions, especially respiratory issues.
